The blood-based analysis of circulating tumor cells or tumor-derived nucleic acids is referred to as “liquid biopsy.” The main target of this analysis is cell-free DNA (cfDNA), which is released into the bloodstream by necrotic and apoptotic cells. Elevated levels of cfDNA are found in patients with cancer and other types of diseases. Since only a small fraction of the circulating DNA is derived from the tumor (ctDNA), highly sensitive detection methods, such as digital droplet PCR (ddPCR) or next-generation sequencing (NGS), are advantageous.
Liquid biopsy applications are manifold, with several striking advantages over conventional tissue analysis. Most importantly, the analysis of liquid biopsies is based on a simple blood draw and, thus, easily repeatable. Our broad liquid biopsy product portfolio covers the targeted analysis of single variants with ddPCR, or a selected panel of cancer-associated genes with NGS technology. Furthermore, for explorative approaches, we also offer comprehensive genomic profiling of cfDNA, for example, using the TSO500ctDNA assay from Illumina.
Application areas of Liquid Biopsies:
- Monitoring a tumor disease
- Monitoring treatment response
- Patient stratification, treatment selection
- Detection of minimal residual disease
- Early detection and profiling of resistance to therapy
CeGaT’s sequencing and digital PCR services offer reliable and accurate insights into liquid biopsies, from nucleic acid extraction to tailored data analysis. Your project will benefit from our long-standing expertise in the diagnostic field and, thus, strict quality standards, as well as practical knowledge.